A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019

BACKGROUND: We evaluated clinical effectiveness of regdanvimab (CT-P59), a severe acute respiratory syndrome coronavirus 2 neutralizing monoclonal antibody, in reducing disease progression and clinical recovery time in patients with mild-to-moderate coronavirus disease 2019 (COVID-19), primarily Alp...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jin Yong, Săndulescu, Oana, Preotescu, Liliana-Lucia, Rivera-Martínez, Norma E, Dobryanska, Marta, Birlutiu, Victoria, Miftode, Egidia G, Gaibu, Natalia, Caliman-Sturdza, Olga, Florescu, Simin-Aysel, Shi, Hye Jin, Streinu-Cercel, Anca, Streinu-Cercel, Adrian, Lee, Sang Joon, Kim, Sung Hyun, Chang, Ilsung, Bae, Yun Ju, Suh, Jee Hye, Chung, Da Rae, Kim, Sun Jung, Kim, Mi Rim, Lee, Seul Gi, Park, Gahee, Eom, Joong Sik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384635/
https://www.ncbi.nlm.nih.gov/pubmed/36043180
http://dx.doi.org/10.1093/ofid/ofac406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384635/
https://www.ncbi.nlm.nih.gov/pubmed/36043180
http://dx.doi.org/10.1093/ofid/ofac406

Ejemplares similares